Similarly, in chronic lymphocytic leukaemia, differential CNT3 expression was observed between fludarabine‐sensitive and resistant patient subgroups, suggesting that CNT3 plays a role in modulating drug responsiveness (Mackey et al. Here, SLC28A3 is linked to B-cell chronic lymphocytic leukemia.